吡柔比星与吉西他滨膀胱灌注化疗治疗膀胱癌的疗效比较

摘要

目的：评价吡柔比星与吉西他滨膀胱内灌注预防膀胱癌术后复发的疗效。方法：将42例保留膀胱手术治疗的膀胱癌患者分为A、B组，A组24例，B组18例。分别使用吡柔比星与吉西他滨进行预防灌注，全部患者均术后即刻膀胱内灌注化疗，每周1次，共6次；以后每月1次直至1~2年，并做随访和疗效比较。结果：A、B两组生存率均为100％；A组复发率为25％（6/24），B组复发率为27.8％（5/18），两组患者2年生存率、复发率比较差异无显著性意义（ P>0.05）。A组和B组用药后膀胱刺激症状发生率、尿道狭窄发生率、全身不良反应发生率比较差异无显著性意义（ P>0.05）。结论：吡柔比星与吉西他滨均可降低膀胱癌术后复发的机率，两者疗效无明显差异。膀胱内灌注预防浅表性膀胱癌术后复发近期疗效满意，副作用较轻，耐受性良好。%Objective:To evaluate the effect of prevention of postoperative recurrence of bladder cancer with intra-vesical between pirarubicin and gemcitabine. Methods:All 42 patients treated with bladder preservation surgery with bladder cancer were divided into A,B group. A group 24 cases,B group 1 8 cases . Respectively prevention infusionwith pirarubicin and gemcitabine. All patients were started one week after intravesical chemotherapy once a week for a total of six times,once a month until after 1 ~2 years,and follow-up. Results:In A,B groups survival rates were 100%,recurrence rate was 25% in group A,27. 8% in group B,2-year survival rate,the recurrence rate difference was not statistically significant. The difference of the incidence of bladder irritation,urethral stricture incidence and systemic adverse reaction rate was not statistically significant. Conclusion:Pirarubicin and gemcitabine can reduce the chances of recurrence of bladder cancer,there is no significant difference in efficacy. Intravesical prophylaxis of super-ficial bladder cancer recurrence recent results were satisfactory,with less serious side effects.